Advertisement
Advertisement

PACB

PACB logo

Pacific Biosciences of California, Inc.

1.60
USD
Sponsored
+0.16
+11.11%
Jun 25, 15:59 UTC -4
Closed
exchange

After-Market

1.57

-0.03
-1.56%

Pacific Biosciences of California, Inc. Profile

About

Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved.

Info & Links

CEO

Christian O. Henry

Headquarters

1305 O'BRIEN DRIVE
MENLO PARK, CA 94025, UNITED STATES

Industry

Medical Instruments

Sector

Medical

Website

www.pacb.com

Auditor

Ernst & Young LLP

Share holders

75

Employees

485

Pacific Biosciences of California, Inc. Statistics

Valuation Measures

Market Capitalization2

489.20M

Enterprise Value

432.90M

Enterprise Value/EBITDA(ttm)

-3.65

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

2.55

Price to Book(mrq)

76.20

Price to Cash(ytd)

1.71

Profitability

Gross Margin(ttm)

27.93%

Operating Margin(ttm)

-99.24%

Profit Margin(ttm)

-360.38%

Return on Equity(ttm)

-326.43%

Return on Invested Capital(ttm)

-75.45%

Return on Assets(ttm)

-19.40%

Income Statement

Revenue(ttm)

160.03M

Revenue Per Share(ttm)

0.52

Gross Profit(ttm)

59.99M

EBITDA(ttm)3

-118.54M

Net Income Available to Common(ttm)

-128.58M

Diluted EPS(ttm)

-1.84

Share Statistics

Beta (5Y Monthly)

2.33

52-Week Change

33.33%

S&P 500 52-Week Change

20.77%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

310.60M

Dividend Yield

0.00%

Float4

294.45M

% Held by Insiders

2.50%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

275.98M

Total Cash Per Share(mrq)

0.89

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

12065.47%

Current Ratio(mrq)

5.15%

Quick Ratio(mrq)

4.47%

Book Value Per Share(mrq)

0.02

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.37

Free Cash Flow(ytd)

-113.92M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement